Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NAGE Niagen Bioscience

Post-Mkt 05-11 17:08:24 EDT

3.98

-0.19

-4.56%

盘后3.97

-0.01-0.25%

17:06 EDT

High4.23	Low3.94	Vol1.95M
Open4.10	D1 Closing4.17	Amplitude6.95%
Mkt Cap318.08M	Tradable Cap204.63M	Total Shares79.92M
T/O7.89M	T/O Rate3.79%	Tradable Shares51.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":3.98,"timestamp":1778529600000,"preClose":4.17,"halted":0,"volume":1950627,"hourTrading":{"tag":"盘后","latestPrice":3.97,"preClose":3.98,"latestTime":"17:06 EDT","volume":4795,"amount":19087.844895,"timestamp":1778533603631,"change":-0.01,"changeRate":-0.002513,"amplitude":0.018769},"delay":0,"changeRate":-0.04556354916067145,"floatShares":51414700,"shares":79919957,"eps":0.210015,"marketStatus":"Post-Mkt","change":-0.19,"latestTime":"05-11 17:08:24 EDT","open":4.1,"high":4.225,"low":3.935,"amount":7893480.3667125,"amplitude":0.069544,"askPrice":4.24,"askSize":10000,"bidPrice":3.97,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.210015,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778544000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":4.17,"preHourTrading":{"tag":"盘前","latestPrice":4.0998,"preClose":4.17,"latestTime":"09:29 EDT","volume":23115,"amount":95099.18517449999,"timestamp":1778506144232,"change":-0.0702,"changeRate":-0.016835,"amplitude":0.021583},"postHourTrading":{"tag":"盘后","latestPrice":3.97,"preClose":3.98,"latestTime":"17:06 EDT","volume":4795,"amount":19087.844895,"timestamp":1778533603631,"change":-0.01,"changeRate":-0.002513,"amplitude":0.018769},"volumeRatio":1.409403,"impliedVol":2.167,"impliedVolPercentile":0.9124},"requestUrl":"/m/hq/s/NAGE/wiki","defaultTab":"wiki","newsList":[{"id":"2634283906","title":"Niagen Bioscience Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634283906","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634283906?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:15","pubTimestamp":1778498100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 07:15 ET (11:15 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633721456","title":"Niagen Bioscience to attend Sohn Investment Conference Emerging Company Pavilion","url":"https://stock-news.laohu8.com/highlight/detail?id=2633721456","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633721456?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:32","pubTimestamp":1778243540,"startTime":"0","endTime":"0","summary":"Niagen Bioscience management scheduled to attend two investor conferences in New York in May 2026.Participation set for May 12 at Sohn Investment Conference, with CFO Ozan Pamir representing company.CEO Rob Fried slated to join CFO Ozan Pamir for investor meetings at Benchmark Consumer One-On-One Conference on May 19.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL3xW2y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633302172","title":"The Benchmark Company Announces 4th Annual Consumer One-on-One Conference in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2633302172","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633302172?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:10","pubTimestamp":1778184600,"startTime":"0","endTime":"0","summary":"NEW YORK, May  07, 2026 (GLOBE NEWSWIRE) -- The Benchmark Company, a subsidiary of StoneX Group Inc. (“StoneX”; NASDAQ: SNEX), is pleased to announce its 4TH Annual Consumer One-on-One Conference at t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290609/11961/en/The-Benchmark-Company-Announces-4th-Annual-Consumer-One-on-One-Conference-in-New-York-City.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU2065731478.USD","FWRG","JJSF","CALM","BK4209","LIND","WEST","SNEX","BK4183","BK4127","LU1941712348.USD","MBUU","DIN","NAGE","BK4102","ANDE","LU2065732104.USD","STKS","FRPT","BJRI","BK4585","BK4121","LU0266013472.USD","KRUS","PATK","BK4588","LU0029874061.USD","LU0757428866.USD","BK4124","LU1169589451.USD","ONEW","BK4212","CHCO","LU1878469433.USD","LU1815336091.USD","SAH","BK4517","LU0054578231.USD","LU1169590202.USD","CHEF","LU1941712264.USD","BK4211","LU0128526141.USD","BK4214","PAG","BK4190","BK4142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633317128","title":"Niagen Bioscience price target lowered to $12 from $13 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633317128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633317128?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:07","pubTimestamp":1778184458,"startTime":"0","endTime":"0","summary":"Roth Capital lowered the firm’s price target on Niagen Bioscience (NAGE) to $12 from $13 and keeps a Buy rating on the shares. The company’s Q1 res...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-price-target-lowered-to-12-from-13-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-price-target-lowered-to-12-from-13-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633667261","title":"Niagen Bioscience posts investor deck outlining NAD+ healthy-aging strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2633667261","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633667261?lang=en_us&edition=fundamental","pubTime":"2026-05-07 07:39","pubTimestamp":1778110749,"startTime":"0","endTime":"0","summary":"Niagen Bioscience investor presentation outlined strategy to expand NAD+ franchise across consumer supplements, IV therapies, injections, skincare.Q1 2026 LTM metrics showed USD 130.4 million revenue, USD 18.6 million net income, USD 66.5 million cash, no debt.Niagen IV and injectables push targeted NAD+ IV market sized at about USD 300 million, positioned as faster to administer with fewer side effects versus NAD+ IV.Early traction cited for Niagen IV, including more than 1,500 clinics onboarded since August 2024, USD 6.4 million ingredient sales since launch.Product development highlighted Niagen NanoCloud topical format, positioned as waterless delivery to reduce degradation risk seen in water-based NAD+ skincare.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL9QdTdZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633168760","title":"Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633168760","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633168760?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:39","pubTimestamp":1778103551,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings SummaryNiagen Bioscience Inc NAGE.OQ reported quarterly adjusted earnings of 7 cents per share for the quarter ended Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL8N41J3O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633590461","title":"Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633590461","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633590461?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:07","pubTimestamp":1778098038,"startTime":"0","endTime":"0","summary":"Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside investments in injections and skincare.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/26/05/52342938/niagen-bioscience-keeps-full-year-sales-forecast-intact-as-q1-revenue-profit-climbs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633159984","title":"BRIEF-Niagen Bioscience Inc Q1 Sales USD 31.474 Million Vs. IBES Estimate USD 30.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633159984","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633159984?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:02","pubTimestamp":1778097765,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Inc Q1 Sales USD 31.474 Million Vs. IBES Estimate USD 30.9 Million\n\n\nMay 06 (Reuters) - Niagen Bioscience Inc Q1 net income USD 6.318 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX9FE0E2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633154911","title":"Niagen Bioscience Inc Outlook FY Revenue Growth 10-15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633154911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633154911?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:02","pubTimestamp":1778097721,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX9FE0E2:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633153159","title":"Niagen Bioscience Inc Q1 EPS USD 0.07 VS. Ibes Estimate USD 0.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2633153159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633153159?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:02","pubTimestamp":1778097721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLX9FE0E2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633159904","title":"Press Release: Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633159904","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633159904?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:02","pubTimestamp":1778097720,"startTime":"0","endTime":"0","summary":"Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million. Niagen Bioscience, Inc.  today announced financial results for the first quarter of 2026.--  Total net sales increased 3% to $31.5 million, including $22.4 million. from Tru Niagen. Excluding the recently sold Analytical Reference. Standards and Services segment from both periods, net sales rose 5% to. --  Gross margin of 63.5%, reflecting continued strength in business mix.divestiture of the Analytical Reference Standards and Services operating. --  Basic and diluted earnings per share were $0.08 and $0.07,--  Working capital increased by $5.4 million quarter-over-quarter.increased inventory levels and timing of receivables, ending with $66.5. to increase; general & administrative expense outlook improved to up. --  In May 2026, the Company launched a clinician-directed telehealth. platform under Niagen Plus, enabling eligible U.S. patients to access. --  In April 2026, the Company ann","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4555","BK4604","BK4588","BK4183","BK4099","TM","BK4232","BK4121","R","NAGE","BK4585","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633928746","title":"Niagen Bioscience Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2633928746","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633928746?lang=en_us&edition=fundamental","pubTime":"2026-05-06 02:59","pubTimestamp":1778007540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 14:59 ET (18:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633142964","title":"Niagen Bioscience Inc  expected to post earnings of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633142964","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633142964?lang=en_us&edition=fundamental","pubTime":"2026-05-05 06:03","pubTimestamp":1777932185,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc  expected to post earnings of8cents a share - Earnings Preview Niagen Bioscience Inc NAGE.OQ NAGE.O is expected to  show a rise in quarterly revenue when it reports  results on M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H2KG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953126","title":"BRIEF-Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953126","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953126?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:35","pubTimestamp":1777898129,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit OfferingMay 4 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE LAUNCHES NIAGEN PLUS TELEHEAL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA1F1LR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632265018","title":"3 Promising Penny Stocks With Market Caps Under $200M","url":"https://stock-news.laohu8.com/highlight/detail?id=2632265018","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632265018?lang=en_us&edition=fundamental","pubTime":"2026-05-01 01:05","pubTimestamp":1777568718,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the market has remained flat, yet it is up 28% over the past year with earnings forecasted to grow by 16% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for growth at lower price points, especially when backed by strong balance sheets and solid fundamentals. This article explores several penny stocks that stand out as hidden gems, potentially offering both stability and upside in today's market landscape.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nysemkt-xtnt/xtant-medical-holdings/news/3-promising-penny-stocks-with-market-caps-under-200m-9","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nysemkt-xtnt/xtant-medical-holdings/news/3-promising-penny-stocks-with-market-caps-under-200m-9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4023","VFF","BK4579","BK4161","BK4166","BK4007","LX","MAPS","BK4209","SIGA","BK4134","BK4583","BK4121","NAGE","BK4191","BK4123","BK4183","BK4198","XTNT","III","LU1046422090.SGD","BABB","CRCT","LU1235295612.USD","FINV","RGP","BK4531","LU0049112450.USD","BK4189","BK4539","NEPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631325636","title":"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), AxoGen (AXGN) and Niagen Bioscience (NAGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631325636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631325636?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:21","pubTimestamp":1777551678,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV), AxoGen (AXGN) and Niagen Bioscience (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-axogen-axgn-and-niagen-bioscience-nage-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-axogen-axgn-and-niagen-bioscience-nage-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0553294199.USD","LU0057025933.USD","LU1839511570.USD","LU0795875169.SGD","HCSG","LU1061106388.HKD","LU0098860793.USD","LU2237443549.SGD","NAGE","LABU","BK4534","LU1244550577.SGD","LU2023251221.USD","LU0861579265.USD","LU1551013342.USD","XLV","AXGN","LU2468319806.SGD","LU1244550494.USD","LU0868494617.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU0211328371.USD","ABBV","LU1496350171.SGD","XBI","LU0456855351.SGD","LU2089284900.SGD","LU0689472784.USD","LU0511384066.AUD","LU1244550221.USD","LU0472753341.HKD","LU0211327993.USD","LU2089283258.USD","LU0234570918.USD","LU0289739343.SGD","LU2133065610.SGD","LU0310800379.SGD","LU0868494708.USD","LU1291159041.SGD","LU0256863902.USD","LU0738911758.USD","LU1989771016.USD","LU0128525929.USD","LU0965509101.SGD","LU0708994859.HKD","LU0320765646.SGD","LU0795875086.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631858270","title":"Pioneer Power Solutions And 2 Other Penny Stocks Worth Watching","url":"https://stock-news.laohu8.com/highlight/detail?id=2631858270","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631858270?lang=en_us&edition=fundamental","pubTime":"2026-04-29 01:05","pubTimestamp":1777395924,"startTime":"0","endTime":"0","summary":"In the last week, the U.S. market has stayed flat, but over the past 12 months, it has risen by 30%, with earnings expected to grow by 16% per annum in the coming years. Amidst these conditions, identifying stocks with solid fundamentals and growth potential is crucial for investors looking to capitalize on market opportunities. Penny stocks may be an outdated term, but they still represent a valuable investment area; when backed by strong financials and balance sheet strength, these smaller...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9612012-choice2-main-header/1585186803878","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9612012-choice2-main-header/1585186803878"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-mrmd/marimed/news/pioneer-power-solutions-and-2-other-penny-stocks-worth-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-mrmd/marimed/news/pioneer-power-solutions-and-2-other-penny-stocks-worth-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4531","BK4134","BK4189","MRMD","BK4121","LU0049112450.USD","BK4539","BK4166","NAGE","BK4209","RPID","BK4191","LU1235295612.USD","VFF","LX","BK4579","BK4183","MAPS","III","SIGA","CRCT","BK4182","BABB","PPSI","BK4583","BK4007","BK4023","LU1046422090.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630071313","title":"BRIEF-Niagen Bioscience Adds Olympia Pharmaceuticals To 503B Compounding Partner Network For Niagen Plus™","url":"https://stock-news.laohu8.com/highlight/detail?id=2630071313","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630071313?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:07","pubTimestamp":1777381657,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Adds Olympia Pharmaceuticals To 503B Compounding Partner Network For Niagen PlusApril 28 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE ADDS OLYMPIA PHARMACEUTICALS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630790304","title":"Niagen Bioscience partners with Olympia Pharmaceuticals for Niagen Plus compounding, distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2630790304","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630790304?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:35","pubTimestamp":1777379749,"startTime":"0","endTime":"0","summary":"Niagen Bioscience entered partnership with Olympia Pharmaceuticals to compound and distribute pharmaceutical-grade Niagen for Niagen Plus intravenous and injectable products.Deal expands Niagen Bioscience 503B outsourcing network alongside Wells Pharma of Houston, diversifying supply chain for clinic demand.Olympia will manufacture liquid compounded vials, widening Niagen Plus product availability across Olympia clinic network.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLYJp4h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630304784","title":"Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™","url":"https://stock-news.laohu8.com/highlight/detail?id=2630304784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630304784?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:33","pubTimestamp":1777379598,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.niagenplus.com","stockEarnings":[{"period":"1week","weight":-0.1402},{"period":"1month","weight":-0.0935},{"period":"3month","weight":-0.1981},{"period":"6month","weight":-0.3904},{"period":"1year","weight":-0.5487},{"period":"ytd","weight":-0.3443}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":" ","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.045249},{"month":2,"riseRate":0.5,"avgChangeRate":0.181088},{"month":3,"riseRate":0.3,"avgChangeRate":0.049759},{"month":4,"riseRate":0.6,"avgChangeRate":0.039691},{"month":5,"riseRate":0.454545,"avgChangeRate":0.00836},{"month":6,"riseRate":0.6,"avgChangeRate":0.068253},{"month":7,"riseRate":0.5,"avgChangeRate":-0.007412},{"month":8,"riseRate":0.3,"avgChangeRate":-0.041379},{"month":9,"riseRate":0.3,"avgChangeRate":-0.054309},{"month":10,"riseRate":0.2,"avgChangeRate":-0.056092},{"month":11,"riseRate":0.7,"avgChangeRate":0.200397},{"month":12,"riseRate":0.3,"avgChangeRate":-0.024057}],"exchange":"NASDAQ","name":"Niagen Bioscience","nameEN":"Niagen Bioscience"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Niagen Bioscience(NAGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Niagen Bioscience,NAGE,Niagen Bioscience股票,Niagen Bioscience股票老虎,Niagen Bioscience股票老虎国际,Niagen Bioscience行情,Niagen Bioscience股票行情,Niagen Bioscience股价,Niagen Bioscience股市,Niagen Bioscience股票价格,Niagen Bioscience股票交易,Niagen Bioscience股票购买,Niagen Bioscience股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Niagen Bioscience(NAGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Niagen Bioscience(NAGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}